• 1
    Porte RJ, Molenaar IQ, Begliomini B, Groenland THN, Januszkiewicz A, Lindgren L, et al. Aprotinin and transfusion requirements in orthotopic liver transplantation: A multicentre randomized double-blind study. Lancet 2000; 355: 13031309.
  • 2
    Porte RJ, Bontempo FA, Knot EA, Lewis JH, Kang YG, Starzl TE. Systemic effects of tissue plasminogen activator-associated fibrinolysis and its relationship to thrombin generation in orthotopic liver transplantation. Transplantation 1989; 47: 978984.
  • 3
    Kang Y, Lewis JH, Navalgund A, Russell MD, Bontempo FA, Niren LS, Starzl TE. Epsilon-aminocaproic acid for treatment of fibrinolysis during liver transplantation. Anesthesiology 1987; 66: 766773.
  • 4
    Ramsay MAE. The use of antifibrinolytic agents results in a reduction in transfused blood products during liver transplantation. Liver Transpl 1997; 3: 665674.
  • 5
    Mallett SV, Cox D, Burroughs AK, Rolles K. Aprotinin and reduction of blood loss and transfusion requirements in orthotopic liver transplantation. Lancet 1990; 336: 886887.
  • 6
    Gitter R, Aliviztos P, Capehart J, Ramsay M, Jett GK. Aprotinin and aortic cannula thrombosis. J Thorac Cardiovasc Surg 1996; 112: 537538.
  • 7
    Alvarez JM, Chandraratna H, Newman MA, Levy JH. Case 3—1999. Intraoperative coronary thrombosis in association with low-dose aprotinin therapy. J Cardiothorac Vasc Anesth 1999; 13: 623628.
  • 8
    Bohrer H, Fleischer F, Lang J, Vahl C. Early formation of thrombi on pulmonary artery catheters in cardiac surgical patients receiving high-dose aprotinin. J Cardiothorac Vasc Anesth 1990; 4: 222225.
  • 9
    Heindel SW, Mill MR, Freid EB, Valley RD, White GC, Norfleet EA. Fatal thrombosis associated with a hemi-fontan procedure, heparin-protamine reversal, and aprotinin. Anesthesiology 2001; 94: 369371.
  • 10
    Fitzsimons MG, Peterfreund RA, Raines DE. Aprotinin administration and pulmonary thromboembolism during orthotopic liver transplantation: Report of two cases. Anesth Analg 2001; 92: 14181421.
  • 11
    Baubillier E, Cherqui D, Dominique C, Khalil M, Bonnet F, Fagniez PL, Duvaldestin P. A fatal thrombotic complication during liver transplantation after aprotinin administration. Transplantation 1994; 57: 16641666.
  • 12
    Dentz ME, Slaughter TF, Mark JB. Early thrombus formation on heparin-bonded pulmonary artery catheters in patients receiving epsilon aminocaproic acid. Anesthesiology 1995; 82: 583586.
  • 13
    Plotkin JS, Johnson LB, Kuo PC. Intracardiac thrombus formation during orthotopic liver transplantation: A new entity or an old enemy? Transplantation 1996; 61: 1131.
  • 14
    Tubbs RR, Benjamin SP, Dohn DE. Recurrent subarachnoid hemorrhage associated with aminocaproic acid therapy and acute renal artery thrombosis. Case report. J Neurosurg 1979; 51: 9497.
  • 15
    Hoffman EP, Koo AH. Cerebral thrombosis associated with Amicar therapy. Radiology 1979; 131: 687689.
  • 16
    Ellis JE, Lichtor JL, Feinstein SB, Chung MR, Polk SL, Broelsch C, et al. Right heart dysfunction, pulmonary embolism, and paradoxical embolization during liver transplantation. A transesophageal two-dimensional echocardiographic study. Anesth Analg 1989; 68: 777782.
  • 17
    Gologorsky E, De Wolf AM, Scott V, Aggarwal S, Dishart M, Kang Y. Intracardiac thrombus formation and pulmonary thromboemblism immediately after graft reperfusion in 7 patients undergoing liver transplantation. Liver Transpl 2001; 7(9): 783789.
  • 18
    Havel M, Gravenwoger F, Schneider J, Laufer G, Wollenek G, Owen A, et al. Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood. J Thorac Cardiovasc Surg 1994; 107: 807810.
  • 19
    Royston D. Intraoperative coronary thrombosis: Can aprotinin be incriminated? J Cardiothorac Vasc Anesth 1994; 8: 137141.
  • 20
    Smith PK, Muhlbaier LH. Aprotinin. Safe and effective only with the full-dose regimen. Ann Thorac Surg 1996; 62: 15751577.
  • 21
    Alderman EL, Levy JH, Rich JB, Nili M, Vidne B, Schaff H, et al. Analyses of coronary graft patency after aprotinin use: Results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. J Thorac Cardiovasc Surg 1998; 116: 716730.
  • 22
    Molenaar IQ, Legnani C, Groenland THN, Palareti G, Begliomini B, Terpstra OT, Porte RJ. Aprotinin in orthotopic liver transplantation: Evidence for a prohemostatic, but not a prothrombotic, effect. Liver Transpl 2001; 7: 896903.
  • 23
    Molenaar IQ, Porte RJ. Aprotinin and thromboembolism in liver transplantation: Is there really a causal effect? Anesth Analg 2002; 94: 13671368.
  • 24
    Speekenbrink RG, Bertina RM, Espana F, Wlidevuur CR, Eijsman L. Activation of the protein C system during cardiopulmonary bypass with and without aprotinin. Ann Thorac Surg 1998; 66: 19982002.
  • 25
    Robbins P, Forrest M, Fanning S, Royston D. Use of aprotinin therapy in a patient with factor V Leiden. Anesth Analg 1997; 84(3): 694698.
  • 26
    Gonzalez-Conejero R, Lozano ML, Rivera J, Corral J, Iniesta JA, Moraleda JM, Vicente V. Polymorphisms of platelet membrane glycoprotein 1b-alpha associated with arterial thrombotic disease. Blood 1998; 92: 27712776.
  • 27
    Murata M, Matsubara Y, Kawano K, Zama T, Aoki N, Yoshino H, et al. Coronary artery disease and polymorphisms in a receptor mediating shear stress-dependent platelet activation. Circulation 1997; 96: 32813286.
  • 28
    Shore-Lesserson L, Manspeizer HE, DePerio M, Francis S, Vela-Cantos F, Ergin MA. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 1999; 88: 312319.